Shots:
- The global program includes two P-III studies assessing vadadustat (PO) vs darbepoetin alfa (inj.) in a ratio (1:1) in incident dialysis patients (Correction/Conversion) and prevalent dialysis patients (Conversion), in ~3,923 adult patients on dialysis with anemia due to CKD
- The presentation expands on previously reported positive data showing vadadustat achieved clear and consistent results across 1EPs & 2EPs
- Vadadustat is an oral HIF-PH inhibitor designed to mimic the physiologic effect of altitude on oxygen availability and is also being evaluated in P-III PRO2TECT for anemia due to CKD in adult patients, not on dialysis. The company plans to submit NDA to the US FDA for anemia due to CKD in adult dialysis-dependent and non-dialysis dependent patients in 2021
Click here to read full press release/ article | Ref: Akebia | Image: Akebia
The post Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for Anemia Due to CKD at ASN Kidney Week first appeared on PharmaShots.
